No­var­tis ad­justs busi­ness unit names in prepa­ra­tion for San­doz gener­ics and biosim­i­lars spin­off

No­var­tis is mod­i­fy­ing its busi­ness units’ names to re­flect its full fo­cus on in­no­v­a­tive med­i­cines when San­doz spins off with gener­ics and biosim­i­lars lat­er this …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.